Biota contracts with AMRI to develop laninamivir for 'flu in support of US NDA
This article was originally published in Scrip
Executive Summary
The Australian company Biota has chosen AMRI, a contract research organisation based in Albany, New York, to further develop the second-generation flu product CS-8958 (laninamivir) – with AMRI providing services to support an NDA to the US FDA. The product is already marketed as Inavir in Japan by Daiichi Sankyo, the drug’s originator, but that is the only market where it is available.